Journal Information
Vol. 13. Issue 3.
Pages 397-418 (May - June 2007)
Share
Share
Download PDF
More article options
Vol. 13. Issue 3.
Pages 397-418 (May - June 2007)
Full text access
Tratamento da tuberculose latente: Revisão das normas, 2006
Treatment of latent tuberculosis infection: Update of guidelines, 2006
Visits
498
Raquel Duarte, Joana Amado, Helena Lucas, José Manuel Sapage
Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia
This item has received
Article information
Resumo

A Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia, sentindo a necessidade de criar normas de actuação referentes à terapêutica da tuberculose latente, coordenou a elaboração de um conjunto de recomendações, com vista a uniformizar os procedimentos nesta área. Para a elaboração do presente documento, contou com a colaboração de elementos das sociedades portuguesas de Medicina Interna, de Pediatria e de Doenças Infecciosas. Procedeu-se a uma revisão e actualização das normas para o rastreio e tratamento da tuberculose latente no adulto imunocompetente e na criança, bem como em adultos e crianças infectadas pelo vírus da imunodeficiência humana. As presentes normas devem ser entendidas como linhas gerais de orientação, e a sua aplicação não deve dispensar a análise de cada caso individual.

Palavras-chave:
Tuberculose latente
rastreio
quimioprofilaxia
terapêutica
Abstract

The Tuberculosis Working Group of the Portuguese Society of Pulmonology, feeling the need to develop guidelines for the diagnosis and treatment of latent tuberculosis infection, compiled a set of recommendations, in view to standardize procedures on this area. This document was prepared in collaboration with the Portuguese Societies of Internal Medicine, Pediatrics and Infectious Diseases. A review and update of guidelines for tracing and treatment of latent tuberculosis infection was made, concerning immunocompetent children and adults, as well as immunocompromised children and adults due to HIV infection. It is understood that these guidelines are to be used as general recommendations, and they should not replace the individual analysis of each case.

Key-words:
Latent tuberculosis infection
tracing
chemoprophylaxis
treatment
Full text is only aviable in PDF
Bibliografia
[1.]
Dados Estatísticos da Direcção Geral da Saúde.
Programa Nacional de Luta contra a Tuberculose (PNT).
Março de, (2003),
[2.]
A. Gomes, J.M. Carvalho, M.C. Gomes.
Comissão de Trabalho de Tuberculose da SPP. Tuberculinas.
Rev Port Pneumol, 1 (1995), pp. 229-239
[3.]
A. Lalvani, A.A. Pathan, et al.
Rapid Detection of Mycobacterium tuberculosis Infection by Enumeration of Antigen-specific T Cells.
Am J Respir Crit Care Med, 163 (2001), pp. 824-828
[4.]
P.F. Barnes.
Diagnosing Latent Tuberculosis Infection. The 100-year Upgrade.
Am J Respir Crit Care Med, 163 (2001), pp. 807-808
[5.]
Centers for Disease Control and Prevention.
Guidelines for Using the QuantiFERON-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection.
MMWR, 52 (2003), pp. 15-18
[6.]
F. Neves Almeida, M.H. Seabra, et al.
Verificação da Alergia pós-vacinal por BCG. Utilização do Mantoux a 10 UT de PR 23.
J Médico, 123 (1992), pp. 360-362
[7.]
N.J. Thompson, J.L. Glassroth, et al.
The Booster Phenomenon in Serial Tuberculin Testing.
Am Rev Resp Dis, 119 (1979), pp. 587-597
[8.]
Villar M. Propostas para a Interpretação e Utilização, no Dia a Dia, da Prova Tuberculínica. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[9.]
Pereira L, Marques L, et al. Diagnóstico e Tratamento da Tuberculose em Pediatria. Recomendações das Secções de Pneumologia e Infecciologia Pediátrica da Sociedade Portuguesa de Pediatria.
[10.]
Rui Sarmento e Castro.
Tuberculose em doentes infectados pelo vírus da imunodeficiência humana.
Tese de Mestrado em Saúde Pública, (1999),
[11.]
Centers for Disease Control and Prevention.
Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations.
MMWR, 46 (1997), pp. 1-10
[12.]
L. Wang, M.O. Turner, et al.
A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements.
Thorax, 57 (2002), pp. 804-809
[13.]
P.G. Smith.
BCG vaccination.
Clinical Tuberculosis, pp. 299-300
[14.]
J. Ninane, A. Grymonprez, et al.
Disseminated BCG in HIV infection.
Archives of Disease in Childhood, 63 (1998), pp. 1268-1269
[15.]
S. Lallement-Le Coeur, M. Lallement, et al.
Bacillus Calmette-Guérin immunization in infants born to HIV-1 seropositive mothers.
AIDS, 5 (1991), pp. 195-199
[16.]
P. Msellati, et al.
BCG vaccination and pediatric HIV infection – Rwanda 1988-1990.
Morbid. Mortal. Weekly Rep., 40 (1991), pp. 833-836
[17.]
2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. http://www.aidsinfo.nih.gov.
[18.]
Carvalho JM. Profilaxia da Tuberculose: O BCG e a Quimioprofilaxia. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[19.]
C. Barreto, et al.
Tratamentos curtos em Tuberculose infantil.
Rev Port Pediatria, 20 (1989), pp. 239-244
[20.]
American Thoracic Society.
Centers for Disease Control and Prevention. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.
Am J Respir Crit Care Med, 161 (2001), pp. S221-S247
[21.]
D.L. Cohn.
Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control.
Clin Infect Dis, 31 (2000), pp. 120-124
[22.]
H.F. Lecoeur, C. Truffot-Pernot, J.H. Grosset.
Experimental Short-course Preventive Therapy of Tuberculosis with Rifampin and Pyrazinamide.
Am Rev Resp Dis, 140 (1989), pp. 1189-1193
[23.]
J.E. Stout, J.J. Engemann, et al.
Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 824-827
[24.]
M. Narita, M. Kellman, et al.
Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection.
Chest, 122 (2002), pp. 1292-1298
[25.]
J.M. Carvalho, P. Pamplona.
Normas para a Quimioprofilaxia da Tuberculose.
Boletim da SPP, (2000),
[26.]
Centers for Disease Control and Prevention.
Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors.
MMWR, 49 (2000), pp. 185-189
[27.]
American Thoracic Society.
Centers for Disease Control and Prevention. Infectious Diseases Society of America. Treatment of Tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[28.]
Diniz A. Tuberculose e Infecção pelo VIH: o Tratamento. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[29.]
WorKing Group on Antiretroviral therapy:and Medical Management of Infants.
Children and Adolescents with HIV Infection. Antiretroviral therapy and Medical Management of Pediatric HIV Infection.
Pediatrics, 102 (1998), pp. 1005-1057
[30.]
Working Group on Antiretroviral therapy and Medical Managemment of HIV, Guidelines for the use of antiretroviral agents in Pediatric HIVinfection. 2001;.(1-67).

Apoio científico de: Sociedade Portuguesa de Medicina Interna, Sociedade Portuguesa de Pediatria e Sociedade Portuguesa de Doenças Infecciosas.

Copyright © 2007. Sociedade Portuguesa de Pneumologia
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?